Zai Lab Partner, GSK, Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer - TC Read more about Zai Lab Partner, GSK, Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer - TC
Dr. Samantha Du, Zai Lab Founder and CEO, to Participate in Forbes Global CEO Conference - TC Read more about Dr. Samantha Du, Zai Lab Founder and CEO, to Participate in Forbes Global CEO Conference - TC
Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer - TC Read more about Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer - TC
Zai Lab Announces Financial Results and Corporate Update for the Six Months Ended June 30, 2019 - TC Read more about Zai Lab Announces Financial Results and Corporate Update for the Six Months Ended June 30, 2019 - TC
Zai Lab Announces Publication of Pharmacokinetic Study of Niraparib in Chinese Ovarian Cancer Patients - TC Read more about Zai Lab Announces Publication of Pharmacokinetic Study of Niraparib in Chinese Ovarian Cancer Patients - TC
Zai Lab Announces Upcoming Presentations at September Conferences - TC Read more about Zai Lab Announces Upcoming Presentations at September Conferences - TC
Zai Lab to Report Financial Results for the Six Months Ended June 30, 2019 and Provide Corporate Update on September 3, 2019 - TC Read more about Zai Lab to Report Financial Results for the Six Months Ended June 30, 2019 and Provide Corporate Update on September 3, 2019 - TC
China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China - TC Read more about China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China - TC
Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China - TC Read more about Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China - TC
Zai Lab Announces Approval to Commercialize ZEJULA (Niraparib) in Macau for Patients with Relapsed Ovarian Cancer - TC Read more about Zai Lab Announces Approval to Commercialize ZEJULA (Niraparib) in Macau for Patients with Relapsed Ovarian Cancer - TC